These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6119765)

  • 21. Compliance to therapy in patients on a maintenance dose of sulfasalazine.
    van Hees PA; van Tongeren JH
    J Clin Gastroenterol; 1982 Aug; 4(4):333-6. PubMed ID: 6126499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
    Klotz U
    Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapy of inflammatory bowel disease. Part 1. Sulfasalazine.
    Das KM
    Postgrad Med; 1983 Dec; 74(6):141-8, 150-1. PubMed ID: 6139795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disposition of salicylazosulfapyridine (Azulfidine) and metabolites in human breast milk.
    Berlin CM; Yaffe SJ
    Dev Pharmacol Ther; 1980; 1(1):31-9. PubMed ID: 6108198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of serum concentrations of sulphasalazine and some of its metabolites after therapy by the oral or rectal route.
    Ashworth M; Arthur M; Turmer AD; Smith PR
    Pharmatherapeutica; 1984; 3(8):551-5. PubMed ID: 6142465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.
    Clarke DF; George D; Milsap RL; Pogonowska-Wala E; Owerbach J; Lebenthal E; Jusko WJ
    Pediatr Pharmacol (New York); 1982; 2(4):323-33. PubMed ID: 6152489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis.
    Azad Khan AK; Truelove SC
    Gut; 1980 Aug; 21(8):706-10. PubMed ID: 6107264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical pharmacokinetics of sulphasalazine.
    Das KM; Dubin R
    Clin Pharmacokinet; 1976; 1(6):406-25. PubMed ID: 15752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats.
    Das KM; Chowdhury JR; Zapp B; Fara JW
    Gastroenterology; 1979 Aug; 77(2):280-4. PubMed ID: 36326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Long-term therapy in ulcerative colitis and Crohn's disease].
    Malchow H
    Fortschr Med; 1979 Aug; 97(29):1253-60. PubMed ID: 457018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time course of free and N4-acetylated sulfapyridine concentrations in the plasma and saliva of man after sulfasalazine (salicylazosulfapyridine) administration: preliminary findings.
    Bates TR; Blumenthal HP; Pieniaszek HJ
    Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):183-9. PubMed ID: 9675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relapse-preventing effect of methyl-salazosulphapyridine compared to salazosulphapyridine during long-term treatment of ulcerative colitis. A double-blind controlled trial.
    Riis P; Binder V; Kristensen M; Folkenborg O; Holtz A; Jarnum S
    Scand J Gastroenterol; 1979; 14(3):257-60. PubMed ID: 35824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Crohn's disease. Has there been progress in its treatment?].
    Berenguer J
    Med Clin (Barc); 1984 Jun; 83(2):61-4. PubMed ID: 6147447
    [No Abstract]   [Full Text] [Related]  

  • 35. Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).
    van Hees PA; Tuinte JH; van Rossum JM; van Tongeren JH
    Gut; 1979 Apr; 20(4):300-4. PubMed ID: 36332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.
    Sharp ME; Wallace SM; Hindmarsh KW; Brown MA
    Eur J Clin Pharmacol; 1981; 21(3):243-50. PubMed ID: 6119205
    [No Abstract]   [Full Text] [Related]  

  • 37. Salazosulfapyridine and metabolites in fetal and maternal body fluids with special reference to 5-aminosalicylic acid.
    Ambrosius Christensen L; Rasmussen SN; Hansen SH; Bondesen S; Hvidberg EF
    Acta Obstet Gynecol Scand; 1987; 66(5):433-5. PubMed ID: 2892343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sulphasalazine-induced leucopenia in a patient with renal dysfunction.
    Teshima D; Hino B; Makino K; Yano T; Itoh Y; Joh Y; Iida M; Oishi R
    J Clin Pharm Ther; 2003 Jun; 28(3):239-42. PubMed ID: 12795783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome.
    Mogadam M; Dobbins WO; Korelitz BI; Ahmed SW
    Gastroenterology; 1981 Jan; 80(1):72-6. PubMed ID: 6108894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease.
    Shaffer JL; Kershaw A; Houston JB
    Br J Clin Pharmacol; 1986 Apr; 21(4):431-5. PubMed ID: 2871853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.